Disopyramide showed no clear difference in recurrence of atrial fibrillation compared with placebo or no treatment (low certainty).
It is very uncertain whether disopyramide changes all‐cause mortality compared with placebo or no treatment (very low certainty).
Disopyramide showed no clear difference in withdrawals due to adverse effects compared with placebo or no treatment (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether disopyramide changes stroke compared with placebo or no treatment (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether lidocaine changes ventricular fibrillation compared with disopyramide (very low certainty).
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): asystole compared with disopyramide (very low certainty).
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): sinoatrial block compared with disopyramide (very low certainty).
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): cardiac blocks… compared with disopyramide (very low certainty).
It is very uncertain whether lidocaine changes all‐cause mortality compared with disopyramide (very low certainty).
It is very uncertain whether lidocaine changes cardiac mortality compared with disopyramide (very low certainty).